Moody's Investors Service announced on July 4, 2026, that HeartFlow, Inc. secured a B2 corporate family rating following a $200 million convertible debt issuance. The agency cited a 40% year-over-year growth in the adoption of its cardiac imaging software for the rating. Concurrently, Iovance Biotherapeutics is preparing for a multi-regulatory catalyst year in 2026, with a potential label expansion for its cell therapy, lifileucel, under review by the U.S. Food and Drug Administration. The contrast between one firm's commercial scale-up and another's pivotal approval pathway defines the investment debate for the year.
Context — why this matters now
Medical technology and biotechnology sectors are undergoing divergent pressures in mid-2026. Persistent high interest rates have tightened capital availability for pre-revenue biotechs, making late-stage de-risking events critical for valuations. For commercial-stage medtech firms, the focus has shifted to execution, gross margin expansion, and demonstrating durable reimbursement pathways amid hospital budget scrutiny.
HeartFlow's non-invasive FFR-CT software for assessing coronary artery disease reached a commercial inflection point in 2025. The technology gained a Category I Current Procedural Terminology (CPT) code, streamlining insurance reimbursement. This administrative milestone directly fueled the 40% procedural volume growth Moody's highlighted, transforming the company's cash flow profile and enabling its recent debt raise.
Iovance's immediate catalyst chain is clinical and regulatory. The FDA accepted its supplemental Biologics License Application (sBLA) for lifileucel in metastatic melanoma in Q4 2025, with a Prescription Drug User Fee Act (PDUFA) action date set for Q2 2026. Success would expand the therapy's label and significantly broaden its addressable patient population, while a delay or rejection would jeopardize near-term revenue growth projections.
Data — what the numbers show
HeartFlow's commercial metrics show clear momentum. The company reported over 150,000 patients assessed using its platform cumulatively by year-end 2025. Procedural volume grew approximately 40% year-over-year in Q1 2026. This drove revenue to an estimated $180 million for fiscal 2025, though the company remains unprofitable on a GAAP basis with an operating margin of -25%. The recent $200 million debt issuance provides a cash runway extending into 2028.
Iovance's financials and market position reflect its development stage. The company holds a market capitalization of approximately $3.2 billion, compared to HeartFlow's estimated $1.8 billion. Iovance reported $12 million in total revenue for Q1 2026, solely from the initial launch of lifileucel in advanced melanoma. Its cash and equivalents stood at $480 million as of March 31, 2026, providing an estimated 24-month runway at current burn rates.
| Metric | HeartFlow | Iovance Biotherapeutics |
|---|
| Q1 2026 Revenue Growth (YoY) | ~40% (procedural) | N/A (recent launch) |
| Market Capitalization | ~$1.8B | ~$3.2B |
| Cash Runway | Into 2028 | ~24 months |
| Key 2026 Catalyst | Commercial execution | FDA sBLA decision (Q2) |
Analysis — what it means for markets / sectors / tickers
The HeartFlow rating underscores a sector rotation into medtech names with proven reimbursement and scaling commercial engines. This benefits peers like SIEMENS HEALTHINEERS AG (SHL.DE) and GE HEALTHCARETECHNOLOGIES INC (GEHC), which also provide advanced cardiac imaging solutions. Successful scale-up validates the software-as-a-medical-device (SaMD) model, potentially lifting valuations for private firms in digital pathology and neurology diagnostics seeking public listings.
For biotech, Iovance's fate is a bellwether for the adoptive cell therapy sector. A positive FDA decision would likely boost peers like ARCELLX INC (ACLX) and TCR2 THERAPEUTICS INC (TCRR), which are developing competing cell therapies for solid tumors. It would signal regulatory comfort with complex, personalized oncology treatments. The counter-argument is that commercial execution risk remains high even with approval; lifileucel's $12 million Q1 revenue suggests a slow initial uptake, and manufacturing scalability is unproven at high volumes.
Positioning data from prime broker reports indicates hedge funds are establishing paired trades, going long established commercial medtech names like HeartFlow while shorting higher-risk, pre-profit biotechs awaiting binary events. Flow is moving into earnings-estimate-eps-surpasses" title="IQVIA Holdings Q2 2026 Earnings Estimate Surpasses $3.20 EPS">healthcare sectors with visible near-term earnings, pressuring the iShares Biotechnology ETF (IBB) relative to the iShares U.S. Medical Devices ETF (IHI).
Outlook — what to watch next
The primary catalyst for Iovance is the FDA's decision on the lifileucel sBLA, with a PDUFA date expected by June 30, 2026. Secondary watch points include the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) opinion, due in Q3 2026, and the presentation of additional Phase 2 clinical data for lifileucel in non-small cell lung cancer at the American Society of Clinical Oncology (ASCO) annual meeting in June.
For HeartFlow, investors will monitor the Q2 2026 earnings report in August for confirmation of sustained 35%+ procedural growth and progress toward operating cash flow breakeven. Key levels to watch include the company's gross margin, which needs to hold above 70%, and its net dollar retention rate, a critical measure of customer value expansion in SaaS-like models.
The broader sector will react to the Centers for Medicare & Medicaid Services (CMS) proposed Medicare Physician Fee Schedule for 2027, expected in July 2026. Any changes to reimbursement rates for FFR-CT or other AI-assisted diagnostics would materially impact HeartFlow's financial model and sector sentiment.
Frequently Asked Questions
What is HeartFlow's FFR-CT and how does it make money?
HeartFlow's FFR-CT Analysis is a non-invasive software tool that uses data from a standard coronary CT angiogram to create a personalized 3D model of a patient's arteries and compute fractional flow reserve. This helps cardiologists assess whether a blockage is impacting blood flow. The company generates revenue primarily by charging healthcare providers a per-analysis fee, typically between $1,000 and $1,500. This fee-based SaaS model provides recurring revenue streams tied to hospital and imaging center procedure volumes.
How does Iovance's lifileucel therapy work for cancer patients?
Lifileucel is a tumor-infiltrating lymphocyte (TIL) therapy, a type of personalized cell therapy for solid tumors. Doctors extract TILs, immune cells that have naturally invaded a patient's tumor, from a surgically removed tumor sample. These cells are then multiplied in a laboratory over several weeks to create billions of cells, which are infused back into the patient after a brief conditioning chemotherapy. The expanded army of TILs is designed to recognize and attack the patient's specific cancer cells.
What are the major risks for investors considering HeartFlow stock?
